Yakuji Nippo

The wall of AG for biosimilars- Inhibiting the spread pointed out one after another Biosimilar Forum

With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

The wall of AG for biosimilars- "Inhibiting the spread" pointed out one after another Biosimilar Forum
October 16th, 2020

The spread of biosimilars has become a significant issue as the next target after achieving a generic product usage rate of 80%. At the "Biosimilar Forum" held on the web by the Biosimilar Council on the 14th, symposiasts pointed out that the authorized generic (AG) of biosimilars that appeared last year hindered the spread of biosimilars. However, opinions were calling for a review of medical fees, including introducing incentives to promote use.

(Continue to the next)

For this translated article in English, CM Plus Corporation shall have the copyright. Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.

A Series of Articles

About the Author

Related Articles

No information is found.

Digital Health
U.S. eHealth Journal

Vol. 81 (Issued at 2023/1/24)

ジャーナル81号のトピックは、Alex Therapeutics社(肺線維症患者向けDTx)、PatientsLikeMe(患者SNSコミュニティ)、LetsGetChecked社(在宅診断テスト)、Sonde Health社(音声バイオマーカー)、Eargo社(OTC補聴器) など

Most Popular


Online Roundtable Discussion Among Clinical Doctors 【Part 5】

LSMIP Editorial Office


Aevice Health Develops Wearable Stethoscopes for Chronic Respiratory Disease Patients

Kazunori Seto M.D.


Interview with Dental Start-up SQRIE - About Social Challenges and Services it Offers

Megumi Kamo DDS, PhD.


Mitsutoshi Yamada


MSA Partners, LLC

Press Room